HEARTCARE-B (06609) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 408 million yuan, representing a year-on-year increase of 46.9%. Gross profit reached 290 million yuan, up 59.3% compared to the previous year. Research and development costs were 40.8 million yuan, a decrease of 30.8% year-on-year. Profit attributable to shareholders was 83.3 million yuan, marking a significant turnaround from a net loss in the prior year. Basic earnings per share were 2.21 yuan.

During the 2025 fiscal year, the company achieved revenue of 408.3 million yuan, a 46.9% increase from the previous year. The group reported a net profit attributable to shareholders of 83.3 million yuan, a substantial improvement from a net loss of approximately 13.6 million yuan in the preceding year. This turnaround was primarily driven by rapid revenue growth across the company's three main business segments: ischemic stroke, hemorrhagic stroke, and interventional access, coupled with enhanced operational efficiency.

In 2025, revenue from the ischemic stroke business grew by 31.8% year-on-year. This growth was mainly due to widespread clinical acceptance of the company's differentiated intracranial thrombus aspiration catheter. The large-lumen aspiration and cascade aspiration technique (CATCH) was included in the "2025 Chinese Expert Consensus on Endovascular Treatment Techniques for Acute Ischemic Stroke." The product has been adopted by over 450 hospitals, leading to a rapid increase in revenue. Additionally, sales of mature products grew rapidly after being included in centralized procurement programs.

For the hemorrhagic stroke business, the company has established a comprehensive solution for aneurysm treatment. Its intracranial stent, which received NMPA recognition as an innovative medical device, was used in approximately 500 hospitals in its first commercial year, rapidly increasing the market share of embolization coils. Furthermore, the company's flow diverter device received NMPA approval in 2025 and has begun clinical promotion and application. As a result, revenue from the hemorrhagic stroke business surged by 223.2% year-on-year in 2025.

In the interventional access segment, the company's star product, the vascular closure device, has been adopted by more than 1,800 hospitals, with annual clinical usage exceeding 200,000 units in terminal hospitals. In 2025, this single product generated revenue exceeding 100 million yuan. The company is also advancing the development and commercialization of its second-generation vascular closure device to further expand its market share.

Overseas market revenue increased by 101.3% in 2025 compared to 2024, attributed to the accelerated registration and promotion of products internationally. The company's thrombectomy stent, occlusion balloon catheter, distal access catheter, and microcatheter have obtained CE or FDA certifications and have received 56 registration certificates in 13 other countries and regions. To date, the company is conducting over 130 product registration projects in 29 additional countries and regions, expanding sales channels to build a foundation for long-term overseas sales growth.